单次给药主要研究目的：考察中国健康受试者在空腹条件下，单次口服不同剂量水平的醋酸艾司利卡西平片的药代动力学（Pharmacokinetics, PK）特征和PK种族敏感性。多次给药主要研究目的：考察中国健康受试者在空腹条件下，多次口服同一剂量的醋酸艾司利卡西平片的药代动力学（Pharmacokinetics, PK）特征。

[Translation]

The main purpose of single-dose administration is to investigate the pharmacokinetic (PK) characteristics and PK ethnic sensitivity of eslicarbazepine acetate tablets at different dose levels in Chinese healthy subjects under fasting conditions. The main purpose of multiple-dose administration is to investigate the pharmacokinetic (PK) characteristics of eslicarbazepine acetate tablets at the same dose in Chinese healthy subjects under fasting conditions.

Start Date24 Sep 2024

Sponsor / Collaborator

Shanghai Shangyao Chinese-Western Pharmaceutical Co., Ltd

[+1]

CTR20220017

/ CompletedPhase 3

一项多中心、随机、双盲、安慰剂对照短期研究及为期一年的开放性、非对照安全扩展研究，评价醋酸艾司利卡西平片用于成人局灶起源癫痫伴有或不伴有局灶进展为双侧强直阵挛发作添加治疗的有效性和安全性以及长期疗效和安全性

[Translation] A multicenter, randomized, double-blind, placebo-controlled short-term study and a one-year open-label, non-controlled safety extension study to evaluate the efficacy and safety of eslicarbazepine acetate tablets as add-on treatment for adults with focal epilepsy with or without focal progression to bilateral tonic-clonic seizures, as well as long-term efficacy and safety

评价醋酸艾司利卡西平片用于成人局灶起源癫痫伴有或不伴有局灶进展为双侧强直阵挛发作添加治疗的疗效。

[Translation]

To evaluate the efficacy of eslicarbazepine acetate tablets as add-on treatment for adults with epilepsy of focal origin with or without focal progression to bilateral tonic-clonic seizures.

Start Date28 Jul 2022

Sponsor / Collaborator

Shanghai ZhongXi Pharmaceutical Co. Ltd.

[+1]

CTR20201102

/ CompletedNot Applicable

醋酸艾司利卡西平片在健康受试者中随机、开放、两周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A randomized, open-label, two-period, double-crossover bioequivalence study of eslicarbazepine acetate tablets in healthy subjects under fasting and fed conditions

研究空腹或餐后状态下，单次口服醋酸艾司利卡西平片受试制剂(规格：400mg，生产商：扬子江药业集团有限公司，提供商：扬子江药业集团北京海燕药业有限公司）与参比制剂（Aptiom®，规格：400mg，持证商：Sunovion Pharmaceuticals Inc. ）在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To study the pharmacokinetic behavior of the test preparation of eslicarbazepine acetate tablets (specification: 400 mg, manufacturer: Yangtze River Pharmaceutical Group Co., Ltd., provider: Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd.) and the reference preparation (Aptiom®, specification: 400 mg, licensee: Sunovion Pharmaceuticals Inc.) in healthy subjects after a single oral administration in the fasting or postprandial state, and to evaluate the bioequivalence of the two preparations. To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date08 Jun 2020

Sponsor / Collaborator

Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd.

100 Clinical Results associated with Eslicarbazepine Acetate

100 Translational Medicine associated with Eslicarbazepine Acetate

100 Patents (Medical) associated with Eslicarbazepine Acetate

748

Literatures (Medical) associated with Eslicarbazepine Acetate

01 Dec 2025·Acta Epileptologica

Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database

Article

Author: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan

Abstract:

Background:

Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods:

This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).

Results:

A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.

Conclusions:

This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.

01 Jul 2025·NEUROCHEMISTRY INTERNATIONAL

Eslicarbazepine, a third-generation anti-seizure medication, inhibits INa but stimulates IK(M)

Article

Author: Hung, Te-Yu ; Wu, Sheng-Nan ; Huang, Chin-Wei

Eslicarbazepine (ESL) is a new antiseizure medication used to treat focal epilepsy. It is not entirely clear how ESL affects the magnitude and gating kinetics of membrane ionic currents, although a few reports have demonstrated its ability to suppress voltage-gated Na⁺ currents (I_Na). With the aid of patch clamp technology, docking prediction, and simulation modeling, this study was conducted to investigate the potential modifications through which ESL may induce on ionic currents, including I_Na, M-type K⁺ current (I_K(M)), and erg-mediated K⁺ current (I_K(erg)), in hippocampal neurons. ESL distinctly inhibited transient I_Na (I_Na(T)) and late I_Na (I_Na(L)), demonstrating greater potency against I_Na(L). ESL shifted the steady-state inactivation curve of I_Na(T) leftward without altering its steepness or activation curve. Additionally, ESL attenuated the tefluthrin-induced enhancement of voltage-dependent hysteresis (Hys_(V)) of persistent I_Na (I_Na(P)). ESL increased I_K(M) in a concentration-dependent manner, shifting its steady-state activation curve toward more depolarized potentials and enhancing Hys(V) strength. It also increased the activity and mean open time of I_K(M) without affecting single-channel conductance. Minimal changes were observed in the magnitude of I_K(erg). Predicted docking analysis revealed that ESL binds to the hNa_V1.7 channel via hydrogen bonds and hydrophobic contacts. Simulation modeling using hippocampal CA1 pyramidal neurons demonstrated that ESL's inhibition of I_Na and stimulation of I_K(M), along with changes in their Hys(V), modulate neuronal action potential firing. Overall, these findings highlight ESL's dual effects on I_Na and I_K(M), revealing mechanisms that likely contribute to its efficacy in treatment of epilepsy.

01 Jun 2025·NEUROSCIENCE

Anti-seizure medication eslicarbazepine affects the synaptic transmission and plasticity in the rat hippocampal synapses

Article

Author: Pathania, Chahat ; Rana, Zubin Singh ; Punnakkal, Pradeep ; Modgil, Abhinav

Patients with epilepsy often have various memory and cognitive impairments and it has been observed that the use of anti-seizure medications (ASMs) sometimes worsen the conditions. Understanding the mechanism of action of ASMs on neuronal networks is key towards answering the comorbidities of epilepsy. We used single cell patch clamp experiments and field recordings to investigate the mechanism of action of the ASM, eslicarbazepine acetate (ESL) on excitability and synaptic transmission in the hippocampal synapses. Moreover, we also investigated the effect of ESL on long-term potentiation (LTP) in the hippocampal synapses. We found that ESL reduces the neuronal excitability and sodium channel currents in a concentration dependent manner. As a known sodium channel blocker, the application of ESL was expected to decrease the amplitude of fEPSPs, but surprisingly an increase in the amplitude of fEPSPs was observed in the presence of 50 μM and 100 μM ESL (clinically relevant concentrations). This increase in fEPSPs was due to the antagonistic effect of ESL on adenosine A1 receptors. We also studied the effect of ESL on synaptic plasticity and found that 50 μM and 100 μM ESL impaired the LTP in hippocampal synapses. This study shows the interaction of ESL with Adenosine A1 receptors and its effect on synaptic plasticity. This may explain the complex and varied efficacy as well as side effects of ASMs in patients.

News (Medical) associated with Eslicarbazepine Acetate

10 Jul 2023

·www.biospace.com

Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities

CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its operations in the U.S. and related markets. The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets, with topline data for two of its Phase 3 candidates in the fields of psychiatry and urology expected this quarter. The company will apply its proprietary advanced analytics and computational technology platforms to support and accelerate its diverse pipeline and commercial programs as well as needed innovations in priority areas of discovery, science, research and development. SMPA's President and Chief Executive Officer, Myrtle Potter, Chief Executive Officer of Biopharma, Adele Gulfo, and Chief Medical Officer, Armin Szegedi, were appointed as Executive Officers of Sumitomo Pharma Co., Ltd. effective July 1, 2023. Innovation Growth Engine "We are pleased to have successfully completed the combination of Sumitomo Pharma's U.S. subsidiaries to form SMPA," said Hiroshi Nomura, Representative Director, President and Chief Executive Officer of Sumitomo Pharma. "As a Sumitomo Pharma Group growth engine, SMPA will focus on maximizing the value of the three key products early, namely, ORGOVYX®, MYFEMBREE®, and GEMTESA®. SMPA will propel scientific and therapeutic innovations to meaningfully impact the evolving health needs of patients in North America and promote development to meet the needs of patients worldwide while also delivering long-term value to society as a stronger, more profitable enterprise." "SMPA comprises some of the brightest talent in drug development, business, science, and technology, operating as one global team to push beyond industry norms and reimagine what's possible," said Myrtle Potter, President and Chief Executive Officer, Sumitomo Pharma America. "Our goal is to realize new treatments with greater benefit to patients while maximizing the potential of our key marketed and development assets to better support areas of critical need and provide potential treatment options where solutions are lacking or do not exist." Commercial Biopharma Business Adele Gulfo, Chief Executive Officer of Biopharma Commercial of Sumitomo Pharma America, said, "SMPA is poised to help solve health challenges in critical disease areas through the exceptional talents and dedication of our highly experienced cross-functional team. SMPA's broad product portfolio, including key brands, ORGOVYX®, MYFEMBREE® and GEMTESA®, will drive the growth of our business and fuel future potential investments. We are deeply committed to the patients we serve in oncology, women's health, urology, rare disease, psychiatry, and neurology, as well as our additional products APTIOM®, RETHYMIC®, and LATUDA®, which healthcare providers and patients continue to rely on." R&D & Pipeline Armin Szegedi, Chief Medical Officer of Sumitomo Pharma America, said, "SMPA has a robust and balanced pipeline, with more than 30 assets and dozens of clinical trials currently underway, to address areas of significant need in psychiatry, neurology, oncology, urology, and regenerative medicine. I am excited about the opportunities we have at SMPA to develop innovative treatments across multiple therapeutic indications, including our lead pipeline candidate, ulotaront, which is being studied in individuals living with schizophrenia, generalized anxiety disorder and the adjunctive treatment of major depressive disorder." Jatin Shah, Chief Oncology Development Officer of Sumitomo Pharma America, added, "SMPA is uniquely positioned with a strong internal discovery and translational research engine committed to the identification and development of innovative, best-in-class, oncology therapies. We are also looking forward to quickly advancing our oncology programs including, TP-3654, an investigational selective oral PIM1 kinase inhibitor, being studied for patients with myelofibrosis (MF) and DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, being evaluated for the treatment of acute myeloid leukemia (AML)." SMPA's leadership team comprises industry-leading experts with deep life sciences expertise across the business and drug development spectrum, as well as quality & manufacturing, commercialization, and data & analytics. We invite you to learn about SMPA's full leadership team and capabilities on our new website: . About Sumitomo Pharma America, Inc. Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. The company's diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets. SMPA leverages proprietary in-house advanced analytics and computational technology platforms to accelerate discovery, research, and help bring novel therapies to patients sooner. SMPA is a Sumitomo Pharma Co., Ltd., company. For more information on SMPA, visit our website or follow us on LinkedIn. About Sumitomo Pharma Co., Ltd. Sumitomo Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and other Asian countries with more than 6,000 employees worldwide. Sumitomo Pharma defines its Mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." Additional information about Sumitomo Pharma is available through its corporate website at . Forward-Looking Statements This press release contains forward-looking statements that may be deemed to be "forward-looking statements" within the meaning of applicable securities laws and Sumitomo Pharma America, Inc. may make related oral, forward-looking statements on or following the date hereof. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Forward-looking statements, by their nature, are subject to a variety of inherent risks and uncertainties that could cause actual results to differ materially from the results projected and reported results should not be considered as an indication of future performance. Many of these risks and uncertainties cannot be controlled by Sumitomo Pharma America, Inc. and you should not place undue reliance on any forward-looking statements. These forward-looking statements are based on information available to Sumitomo Pharma America, Inc. as of the date of this communication and speak only as of the date of this communication. Sumitomo Pharma America, Inc. does not assume any obligation to publicly update any forward-looking statements, except as may be required by law. No information contained on any website referenced in this press release is incorporated by reference herein. Sumitomo Pharma America, Inc. is a registered trademark of Sumitomo Pharma Co., Ltd. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. © 2023 Sumitomo Pharma America, Inc. All rights reserved. SMPA IR / Media Contact: Maya Frutiger VP, Head of Corporate Communications Sumitomo Pharma America, Inc. CorpComms@us.sumitomo-pharma.com View original content to download multimedia: SOURCE Sumitomo Pharma America, Inc.

Executive ChangePhase 3

20 Feb 2009

·www.pharmatimes.com

EMEA calls for Raptiva suspension, issues latest recommendations

On a busy day for the regulator, the European Medicines Agency has recommended that marketing authorisation be suspended for Merck KGaA/Genentech's psoriasis drug Raptiva over possible links between the drug and a rare but deadly brain infection. The EMEA’s Committee for Medicinal Products for Human Use (CHMP) said the benefits of Raptiva (efalizumab) no longer outweigh its risks, because of safety concerns, notably the occurrence of progressive multifocal leukoencephalopathy (PML) in patients taking the medicine. The CHMP noted three confirmed cases of PML in patients who had taken Raptiva for more than three years, two of resulted in the patient’s death, and the agency has received an additional report of a suspected case of PML, “which could not be confirmed”. Nevertheless, following a review, the CHMP has concluded that “Raptiva’s benefits are modest”. In addition to PML, Raptiva is associated with other serious side effects, including Guillain-Barre and Miller-Fisher syndromes, encephalitis, encephalopathy, meningitis, sepsis and opportunistic infections,” the EMEA noted. It added that “there is not enough evidence to identify a group of patients in which the benefits of Raptiva outweigh its risks”. The EMEA’s call for suspension came as its counterpart in the USA, the Food and Drug Administration, issued a public health advisory about the three confirmed reports of PML and the possible fourth case. The FDA stated that it will “take appropriate steps to ensure that the risks of Raptiva do not outweigh its benefits”. Merck, which markets Raptiva in Europe, said it would work with health authorities across the continent "to undertake all necessary measures to comply with the EMEA recommendations." Earlier this week, the Darmstadt-based group noted that it had written off 195 million euros due to “sharply lower sales expectations” for the drug. Staying with the EMEA, the agency has issued the latest list of positive opinions from the CHMP. The drugs recommended for approval include Wyeth’s Conbriza (bazedoxifene) for postmenopausal osteoporosis, Bial’s anti-epileptic Zebinix (eslicarbazepine; see story on today’s elert) and Fresenius’ Removab (catumaxomab) for the removal of cancerous fluid from the abdomen. The CHMP is also recommending approval for Nycomed’s over-the-counter versions of its own heartburn drug Pantozol (pantoprazole) and Teva’s generic version of Novartis’ anti-dementia drug Exelon (rivastigmine). However, it adopted a negative opinion for Biferonex (interferon-beta-1a), from Switzerland’s BioPartners, for multiple sclerosis. BioPartners is appealing the decsion, claiming that Biferonex demonstrated safety and efficacy profiles comparable to established interferon beta-1a products already on the market".

100 Deals associated with Eslicarbazepine Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D09612	Eslicarbazepine Acetate	N03AF04	DB09119

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Epilepsy	South Korea	Whan In Pharmaceutical Co., Ltd.	10 Nov 2020
Epilepsies, Partial	European Union	BIAL-Portela & Cia SA	21 Apr 2009
Epilepsies, Partial	Iceland	BIAL-Portela & Cia SA	21 Apr 2009
Epilepsies, Partial	Liechtenstein	BIAL-Portela & Cia SA	21 Apr 2009
Epilepsies, Partial	Norway	BIAL-Portela & Cia SA	21 Apr 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	Phase 3	Portugal	BIAL-Portela & Cia SA	01 Nov 2010
Neuralgia, Postherpetic	Phase 3	Germany	BIAL-Portela & Cia SA	01 Sep 2010
Epilepsy, Complex Partial	Phase 3	United States	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	United States	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Argentina	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Argentina	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Belgium	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Belgium	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Brazil	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Brazil	Sumitomo Pharma America, Inc.	02 Dec 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06597084 (CTgov)	Phase 2	Stroke \| Seizures \| Epilepsy ... View more	129	ESL 800 mg (Group A)	kekrxfbbhw = canniesxgf jvggzyxgeh (pbuixqpvun, hqclaqzlqt - tzqxssiqtp) View more	-	02 May 2025
				Placebo (Group B)	kekrxfbbhw = scjpkulvez jvggzyxgeh (pbuixqpvun, didxbkuvbv - vclontthaa) View more
IEC2023	Not Applicable	Behavioural disorders	849	Eslicarbazepine Acetate	oyinpyodeg(zjfjrdwqsg) = 43 reports rlxynakjnr (piwauiehif ) View more	-	04 Sep 2023
P4-1.010 (AAN2023)	Not Applicable	Seizures	-	Eslicarbazepine Acetate 400mg/day	frpotwgawl(xbzxpibsmw) = itnuiyxufm qciyvmkeip (vebnwfvfog, 8.6)	Positive	25 Apr 2023
				Eslicarbazepine Acetate 800mg/day	frpotwgawl(xbzxpibsmw) = jjeajtfzgn qciyvmkeip (vebnwfvfog, 6.2)
P14-1.003 (AAN2023)	Phase 3	Seizures	1,447	Eslicarbazepine Acetate 800mg	xwufboytnp(ssddovhkjz) = Incidence of AEs and AEs leading to discontinuation increased with ESL dose wnevjltgpb (bpncyvsmdf ) View more	Positive	25 Apr 2023
				Eslicarbazepine Acetate 1200mg
NCT02484001 (NCT01162460/NCT02484001; EudraCT 2009-011135-13/2015-001243-36, Pubmed \| Ther Adv Neurol Disord)	Phase 3	Seizures plasma lipid levels \| total cholesterol \| low-density lipoprotein (LDL) cholesterol	184	Eslicarbazepine acetate (ESL)	ogqbgpzvhn(fqmbexmeli) = rajyjkbhrt lgnaysgdld (lkfqcbvahp ) View more	Positive	01 Jan 2023
				Controlled-release carbamazepine (CBZ-CR)	ogqbgpzvhn(fqmbexmeli) = rhmckidnbn lgnaysgdld (lkfqcbvahp ) View more
BIA-2093-208 \| BIA-2093-305 (EAN2022)	Phase 2/3	Seizures	-	Eslicarbazepine acetate	fbbqkfxbum(fgvvhlcvpp) = ksvpasddwh mxxbnfbqca (yoggwxsfrs ) View more	Positive	24 Jun 2022
				Placebo	fbbqkfxbum(fgvvhlcvpp) = sfpjfjoymv mxxbnfbqca (yoggwxsfrs ) View more
BIA-2093-304 (EAN2021)	Not Applicable	-	496	Eslicarbazepine acetate 800mg/day	hfgopjovow(xuiqcphwwk) = 7.5% in Part II and not reported in Part III aehqvzsaia (gofdloxpio ) View more	Positive	18 Jun 2021
				Eslicarbazepine acetate 400-1600mg/day
EAN2021	Not Applicable	Pregnancy	3,986	Eslicarbazepine acetate	gafgbrwyuc(beianwescx) = qawekazxvp zakkhavyxi (pheoflzldn ) View more	Positive	18 Jun 2021
EAN2021	Not Applicable	Paediatric infections	-	Perampanel 8mg/d	xvvwcpgklr(ofzvmtxdvl): RR = 0.97 (95% CI, 0.75 - 1.28) View more	-	18 Jun 2021
				Brivaracetam 100mg/d
NCT00957047 \| NCT00957684 \| NCT00988429 (Pubmed \| Epilepsy Res)	Phase 3	Epilepsies, Partial \| Seizures	-	eslicarbazepine acetate (Older adults (≥60 years))	zebqzlzudb(jrumvrgugw) = dexgzuxrqg ajtsavsbsz (bprnrimiyv ) View more	-	01 Jan 2021
				eslicarbazepine acetate (Younger adults (18-59 years))	zebqzlzudb(jrumvrgugw) = buzhfvpqyb ajtsavsbsz (bprnrimiyv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis